Aralez Pharmaceuticals Inc. Form 8-K April 05, 2018

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

# FORM 8-K

## **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  $\mbox{\bf April~3,2018}$ 

## ARALEZ PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

British Columbia, Canada (State or other jurisdiction of incorporation)

001-37691 (Commission File Number) 98-1283375 (IRS Employer Identification No.)

7100 West Credit Avenue, Suite 101, Mississauga, Ontario, Canada

L5N 0E4

(Address of principal executive offices)

the following provisions:

0


0

0

o

(Zip Code)

Registrant s telephone number, including area code: (905) 876-1118



#### Item 1.01. Entry Into A Material Definitive Agreement.

On April 3, 2018, Aralez Pharmaceuticals US Inc. ( Aralez US ), a Delaware company and a wholly-owned, indirect subsidiary of Aralez Pharmaceuticals Inc., a company formed under the laws of the Province of British Columbia, Canada, entered into a Modification of Contract (the Contract Modification ) pursuant to which the United States of America (the Government ) exercised its second renewal option under that certain VA National Contract, effective April 29, 2016, between Aralez US (by novation from AstraZeneca Pharmaceuticals LP) and the Government (the Agreement ), extending the term of the Agreement by one year to April 28, 2019 on the same pricing terms as have been in effect during the April 29, 2017 through April 28, 2018 annual term except for a price decrease to the 200mg SKUs only (which are currently the smallest selling SKUs). Under the Agreement, Aralez US provides products containing metoprolol succinate (sold under the brand name Toprol-XL®) as the active pharmaceutical ingredient at fixed prices to the U.S. Department of Veterans Affairs and certain other United States federal government agencies. The Contract Modification is filed as Exhibit 10.1 to this report and is incorporated herein by reference.

Item 9 01	Financial	Statements ar	nd Evhibite

(d) List of Exhibits

EXHIBIT NO.

DESCRIPTION

10.1 N

Modification of Contract, executed on April 3, 2018, between the United States of America and Aralez Pharmaceuticals US Inc.

2

## EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
10.1	Modification of Contract, executed on April 3, 2018, between the United States of America and Aralez Pharmaceuticals US Inc.
	3

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 5, 2018 ARALEZ PHARMACEUTICALS INC.

By: /s/ Michael Kaseta

Michael Kaseta Chief Financial Officer

4